DE60220441D1 - Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) - Google Patents
Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)Info
- Publication number
- DE60220441D1 DE60220441D1 DE60220441T DE60220441T DE60220441D1 DE 60220441 D1 DE60220441 D1 DE 60220441D1 DE 60220441 T DE60220441 T DE 60220441T DE 60220441 T DE60220441 T DE 60220441T DE 60220441 D1 DE60220441 D1 DE 60220441D1
- Authority
- DE
- Germany
- Prior art keywords
- ppar
- agents
- human
- acid derivatives
- receptor alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104334A SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
SE0104334 | 2001-12-19 | ||
PCT/GB2002/005744 WO2003051822A1 (en) | 2001-12-19 | 2002-12-18 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60220441D1 true DE60220441D1 (de) | 2007-07-12 |
DE60220441T2 DE60220441T2 (de) | 2008-01-24 |
Family
ID=20286433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60214594T Expired - Lifetime DE60214594T2 (de) | 2001-12-19 | 2002-12-18 | Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar) |
DE60220441T Expired - Fee Related DE60220441T2 (de) | 2001-12-19 | 2002-12-18 | Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60214594T Expired - Lifetime DE60214594T2 (de) | 2001-12-19 | 2002-12-18 | Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar) |
Country Status (31)
Country | Link |
---|---|
US (2) | US7256307B2 (de) |
EP (2) | EP1458673B1 (de) |
JP (4) | JP3784804B2 (de) |
KR (2) | KR20040074092A (de) |
CN (3) | CN1293044C (de) |
AR (2) | AR038047A1 (de) |
AT (2) | ATE338743T1 (de) |
AU (2) | AU2002366315A1 (de) |
BR (2) | BR0214988A (de) |
CA (2) | CA2469302A1 (de) |
CY (2) | CY1106276T1 (de) |
DE (2) | DE60214594T2 (de) |
DK (2) | DK1458672T3 (de) |
ES (2) | ES2271381T3 (de) |
HK (2) | HK1068604A1 (de) |
HU (2) | HUP0402022A3 (de) |
IL (3) | IL162331A0 (de) |
IS (2) | IS7309A (de) |
MX (2) | MXPA04006003A (de) |
MY (1) | MY132565A (de) |
NO (2) | NO20043023L (de) |
NZ (2) | NZ533276A (de) |
PL (2) | PL370672A1 (de) |
PT (2) | PT1458672E (de) |
RU (2) | RU2303031C2 (de) |
SE (1) | SE0104334D0 (de) |
SI (2) | SI1458673T1 (de) |
TW (2) | TWI255807B (de) |
UA (2) | UA77460C2 (de) |
WO (2) | WO2003051822A1 (de) |
ZA (2) | ZA200404658B (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
CN1662487A (zh) * | 2002-06-19 | 2005-08-31 | 伊莱利利公司 | 酰胺连接基过氧化物酶体增殖物激活受体调节剂 |
WO2004000790A1 (en) | 2002-06-20 | 2003-12-31 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
US8293751B2 (en) | 2003-01-14 | 2012-10-23 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314129D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US8415364B2 (en) | 2003-11-26 | 2013-04-09 | Duke University | Method of preventing or treating glaucoma |
DK1697306T3 (da) * | 2003-12-15 | 2007-11-12 | Lilly Co Eli | Selektive peroxisomproliferatoraktiverede receptormodulatorer |
NZ552501A (en) | 2004-08-11 | 2010-03-26 | Kyorin Seiyaku Kk | Novel cyclic aminobenzoic acid derivative |
SE0403072D0 (sv) * | 2004-12-16 | 2004-12-16 | Astrazeneca Ab | Pharmaceutically useful salts of carboxylic acid derivates |
JP2008542355A (ja) | 2005-05-31 | 2008-11-27 | ファイザー株式会社 | Vr1アンタゴニストとしての置換アリールオキシ−n−ビシクロメチルアセトアミド化合物 |
WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
TWI331523B (en) * | 2005-12-08 | 2010-10-11 | Nat Health Research Institutes | Vinylsulfonate compounds |
CN101054372B (zh) * | 2006-04-11 | 2010-10-13 | 中国科学院上海药物研究所 | 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途 |
KR100847780B1 (ko) * | 2006-10-26 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제 |
RU2361581C2 (ru) | 2007-09-14 | 2009-07-20 | Закрытое Акционерное Общество "Мастерклон" | Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
EP3777864A1 (de) | 2010-11-08 | 2021-02-17 | Albireo AB | Ibat-hemmer zur behandlung von lebererkrankungen |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP3810581A1 (de) | 2018-06-20 | 2021-04-28 | Albireo AB | Kristallmodifikationen von odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
PE20230234A1 (es) | 2019-12-04 | 2023-02-07 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
WO2023039276A1 (en) * | 2021-09-13 | 2023-03-16 | Curtails Llc | Use of ibat inhibitors and antimicrobials for the treatment of diseases |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE266121C (de) | ||||
BE489216A (de) | 1948-06-05 | 1900-01-01 | ||
US2928840A (en) * | 1958-11-26 | 1960-03-15 | Us Vitamin Pharm Corp | 3-(o-substituted phenyl) oxazolidinediones and process therefor |
GB1081471A (en) | 1963-09-13 | 1967-08-31 | Stauffer Chemical Co | Glycol amide derivatives and use thereof in controlling weed growth |
US3244398A (en) * | 1963-10-28 | 1966-04-05 | Scaramucci Domer | Composite seat ball valve |
AT307640B (de) | 1970-06-18 | 1973-05-25 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen |
BE792364A (fr) | 1971-12-06 | 1973-06-06 | Basf Ag | Derives de substitution du sulfonylglycolanilide |
DE2349256C2 (de) | 1973-10-01 | 1985-08-01 | Basf Ag, 6700 Ludwigshafen | 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide |
DE2828222A1 (de) | 1978-06-28 | 1980-01-10 | Bayer Ag | Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
US4735959A (en) * | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
US5216167A (en) * | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
US5312924A (en) * | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
US5210208A (en) * | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
US6410585B1 (en) * | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
CA2298601A1 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
US6576766B1 (en) | 1997-11-12 | 2003-06-10 | Ariad Pharmaceuticals, Inc. | Signal transduction inhibitors, compositions containing them |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
IL145732A0 (en) | 1999-04-06 | 2002-07-25 | Sankyo Co | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
AU3670900A (en) * | 1999-04-08 | 2000-11-14 | Sankyo Company Limited | Substituted fused imidazole derivatives |
WO2000061585A2 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia (Ubc) | 1,3-dipolar cycloadditions to polypyrrolic macrocycles |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
ES2287016T3 (es) | 1999-04-28 | 2007-12-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de diaril-acido como ligandos del receptor ppar. |
JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
JP2001261612A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
WO2002044127A1 (fr) | 2000-11-29 | 2002-06-06 | Kyorin Pharmaceutical Co., Ltd. | Dérivés d'acide carboxylique substitué |
AU2002222550A1 (en) | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
EP1360172A1 (de) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonisten |
WO2002083616A1 (fr) * | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE |
GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
CN1662487A (zh) | 2002-06-19 | 2005-08-31 | 伊莱利利公司 | 酰胺连接基过氧化物酶体增殖物激活受体调节剂 |
GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2001
- 2001-12-19 SE SE0104334A patent/SE0104334D0/xx unknown
-
2002
- 2002-12-18 AU AU2002366315A patent/AU2002366315A1/en not_active Abandoned
- 2002-12-18 AT AT02804964T patent/ATE338743T1/de not_active IP Right Cessation
- 2002-12-18 PL PL02370672A patent/PL370672A1/xx not_active Application Discontinuation
- 2002-12-18 ES ES02804964T patent/ES2271381T3/es not_active Expired - Lifetime
- 2002-12-18 PT PT02788145T patent/PT1458672E/pt unknown
- 2002-12-18 CN CNB028281233A patent/CN1293044C/zh not_active Expired - Fee Related
- 2002-12-18 EP EP02804964A patent/EP1458673B1/de not_active Expired - Lifetime
- 2002-12-18 CA CA002469302A patent/CA2469302A1/en not_active Abandoned
- 2002-12-18 BR BR0214988-5A patent/BR0214988A/pt not_active IP Right Cessation
- 2002-12-18 MY MYPI20024740A patent/MY132565A/en unknown
- 2002-12-18 NZ NZ533276A patent/NZ533276A/en unknown
- 2002-12-18 SI SI200230424T patent/SI1458673T1/sl unknown
- 2002-12-18 CN CNB2006100071731A patent/CN100406427C/zh not_active Expired - Fee Related
- 2002-12-18 HU HU0402022A patent/HUP0402022A3/hu unknown
- 2002-12-18 DE DE60214594T patent/DE60214594T2/de not_active Expired - Lifetime
- 2002-12-18 TW TW091136519A patent/TWI255807B/zh not_active IP Right Cessation
- 2002-12-18 IL IL16233102A patent/IL162331A0/xx unknown
- 2002-12-18 HU HU0402133A patent/HUP0402133A3/hu unknown
- 2002-12-18 JP JP2003552709A patent/JP3784804B2/ja not_active Expired - Fee Related
- 2002-12-18 PL PL02370673A patent/PL370673A1/xx not_active Application Discontinuation
- 2002-12-18 US US10/499,378 patent/US7256307B2/en not_active Expired - Fee Related
- 2002-12-18 JP JP2003552710A patent/JP3820249B2/ja not_active Expired - Lifetime
- 2002-12-18 MX MXPA04006003A patent/MXPA04006003A/es active IP Right Grant
- 2002-12-18 DK DK02788145T patent/DK1458672T3/da active
- 2002-12-18 UA UA20040604246A patent/UA77460C2/uk unknown
- 2002-12-18 EP EP02788145A patent/EP1458672B1/de not_active Expired - Lifetime
- 2002-12-18 ES ES02788145T patent/ES2286310T3/es not_active Expired - Lifetime
- 2002-12-18 US US10/499,261 patent/US7514471B2/en not_active Expired - Fee Related
- 2002-12-18 RU RU2004116917/04A patent/RU2303031C2/ru not_active IP Right Cessation
- 2002-12-18 PT PT02804964T patent/PT1458673E/pt unknown
- 2002-12-18 CN CNA028281551A patent/CN1620423A/zh active Pending
- 2002-12-18 AT AT02788145T patent/ATE363466T1/de not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009501A patent/KR20040074092A/ko not_active Application Discontinuation
- 2002-12-18 RU RU2004116918/04A patent/RU2300517C2/ru not_active IP Right Cessation
- 2002-12-18 WO PCT/GB2002/005744 patent/WO2003051822A1/en active IP Right Grant
- 2002-12-18 MX MXPA04006004A patent/MXPA04006004A/es active IP Right Grant
- 2002-12-18 TW TW091136518A patent/TWI253444B/zh not_active IP Right Cessation
- 2002-12-18 DK DK02804964T patent/DK1458673T3/da active
- 2002-12-18 UA UA20040604245A patent/UA77987C2/uk unknown
- 2002-12-18 CA CA002470491A patent/CA2470491A1/en not_active Abandoned
- 2002-12-18 DE DE60220441T patent/DE60220441T2/de not_active Expired - Fee Related
- 2002-12-18 WO PCT/GB2002/005738 patent/WO2003051821A1/en active IP Right Grant
- 2002-12-18 NZ NZ533274A patent/NZ533274A/en unknown
- 2002-12-18 SI SI200230570T patent/SI1458672T1/sl unknown
- 2002-12-18 BR BR0214986-9A patent/BR0214986A/pt not_active IP Right Cessation
- 2002-12-18 KR KR10-2004-7009517A patent/KR20040074094A/ko not_active Application Discontinuation
- 2002-12-18 IL IL16233002A patent/IL162330A0/xx unknown
- 2002-12-18 AU AU2002352427A patent/AU2002352427A1/en not_active Abandoned
- 2002-12-19 AR ARP020105004A patent/AR038047A1/es not_active Application Discontinuation
- 2002-12-19 AR ARP020105002A patent/AR038045A1/es unknown
-
2004
- 2004-06-03 IL IL162330A patent/IL162330A/en not_active IP Right Cessation
- 2004-06-11 ZA ZA200404658A patent/ZA200404658B/en unknown
- 2004-06-11 ZA ZA200404657A patent/ZA200404657B/en unknown
- 2004-06-14 IS IS7309A patent/IS7309A/is unknown
- 2004-06-15 IS IS7313A patent/IS7313A/is unknown
- 2004-07-15 NO NO20043023A patent/NO20043023L/no not_active Application Discontinuation
- 2004-07-16 NO NO20043164A patent/NO20043164L/no not_active Application Discontinuation
-
2005
- 2005-02-01 HK HK05100831A patent/HK1068604A1/xx not_active IP Right Cessation
- 2005-02-16 HK HK05101304A patent/HK1068870A1/xx not_active IP Right Cessation
- 2005-08-16 JP JP2005235794A patent/JP2005336209A/ja active Pending
-
2006
- 2006-04-27 JP JP2006123399A patent/JP2006298924A/ja active Pending
- 2006-12-05 CY CY20061101743T patent/CY1106276T1/el unknown
-
2007
- 2007-08-01 CY CY20071101028T patent/CY1106784T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60220441D1 (de) | Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) | |
ATE512594T1 (de) | Verbesserung des zustandes älterer haustiere | |
CY2014003I1 (el) | Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο | |
ATE296619T1 (de) | Feste orale dosierungsform von simethicon | |
MXPA03001495A (es) | Derivados de fenilalanina novedosos. | |
DK1299729T3 (da) | Tidlig diagnosticering af konformationelle sygdomme | |
EE04240B1 (et) | (S)-omeprasooli kaaliumisool | |
DK1237408T3 (da) | Hæld-på-formuleringer | |
EE200200701A (et) | Kõrgkontsentreeritud stabiilsed meloksikaami lahused | |
NO20026209D0 (no) | Endoparasitticidale midler for frivillig oralt inntak av dyr | |
ATE332903T1 (de) | Kondensierte pyridoindolderivate | |
DK1764111T3 (da) | Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi | |
ATE455754T1 (de) | Arylsulfonamid-substituierte hydroxamsäure- derivate | |
DE60036093D1 (de) | Antagonisten des gardos-kanals | |
DK1464641T3 (da) | 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister | |
NO20040702L (no) | Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav | |
DK1216032T3 (da) | Orale formuleringer med kontrolleret frigivelse | |
DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
EE200300434A (et) | Farmatseutiliselt toimivate ühendite kasutamine | |
NO20003799L (no) | Innkorporering av kolesterol senkende midler i konfekt- dosisformer | |
ID30381A (id) | Penggunaan arilalkanoilpiridazina | |
FR2849379B1 (fr) | Encapsulation d'actifs liposolubles | |
FI20020360A0 (fi) | Biologisesti aktiivisen tuotteen uusi käyttö | |
DE50310743D1 (de) | Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat | |
ATE344235T1 (de) | Monohydrat des cis-lithium-cyano-4-[3- (cyclopentyloy)-4- methoxyphenylöcyclohexancarboxylats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |